Posters

Clinical and therapeutic outcomes of topical IFNα-2β in the management of ocular surface squamous neoplasia

Poster Details

First Author: J.Artaechevarria Artieda SPAIN

Co Author(s):    J. San Roman Llorens   A. Garde González   B. García Sandoval   N. Alejandre Alba   I. Jiménez-Alfaro Morote        

Abstract Details

Purpose:

To report the clinical, multimodal imaging and therapeutic outcomes of a series of 35 patients with ocular surface squamous neoplasia and to describe the results of adjuvant therapy with IFNα-2β.

Setting:

The tertiary referral University Hospital Fundación Jiménez Díaz, Madrid, Spain.

Methods:

A retrospective cases series of patients that consulted our hospital from January 2010 to March 2020 with any type of ocular surface squamous neoplasia (OSSN): conjunctival or corneal intraepithelial neoplasia (CIN), squamous cell carcinoma (SCC) and mucoepidermoid carcinoma (MEC). Diagnose included clinical history, complete ophthalmological examination, anterior segment-OCT and histologic analysis. Treatment depended on the diagnosis, and included topical IFNα-2β, simple excision, excision with conjunctival autograft and excision with amniotic membrane graft. Adjuvant topical IFNα-2β was used four times a day in selected patients. Recurrences and complications were noted.

Results:

36 cases of OSSN of 35 patients were included. 20 were male (57.1%) and 15 female (42.9%). Histologic analysis resulted in 10 cases of CIN I (23.25%), 8 CIN II (18.6%), 15 CIN III (30.2%), 3 SCC (6.9%) and none MEC. 1 patient received topical IFNα-2β (2.7%), 12 patients had simple excision (32.4%), 22 had excision with conjunctival autograft (59.4%) and 2 excision with amniotic membrane graft (5.4%). Adjuvant topical IFNα-2β was used in 32 eyes (86.5%). 4 patients presented recurrence (10.8%), of which two (5.4%) had been treated with IFNα-2β previously. No complications related to IFNα-2β were observed.

Conclusions:

OSSN is a group of different ocular surface diseases that present different grades of cellular atypia. Once surgically removed, topical IFNα-2β can be considered a well-tolerated, safe and effective adjuvant therapy which reduces the risk of recurrence. Since definitive guidelines are not available, we propose a treatment protocol of 3 months for CIN I, 3 to 6 months in CIN II and 6 months in CIN III. Close observation could be optional in cases with low-grade atypia.

Financial Disclosure:

None